Welcome to our dedicated page for Pyxus Internatio SEC filings (Ticker: PYYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pyxus International's SEC filings document current-report disclosures for a global value-added agricultural company whose PYYX security is identified with an OTCID designation. Recent Form 8-K reports furnish Item 2.02 results of operations and financial condition, with earnings releases attached as exhibits and Inline XBRL cover data.
The filings disclose financial and operating performance categories such as sales and operating revenues, leaf product revenue, processing and other revenues, gross margin, operating income, adjusted EBITDA, guidance, inventory activity, customer shipment timing, and crop purchasing across its agricultural platform. They also identify the registrant's Virginia corporate status and state that no securities are registered under Section 12(b) of the Exchange Act.
Pyxus International reported strong fourth-quarter and solid full-year 2026 results, highlighted by record profitability and improved leverage. Q4 sales rose 35.2% year-over-year to $678.2 million, driven by higher leaf sales volumes from Africa and North America, lifting gross profit to $94.4 million and operating income to $43.7 million.
For the year ended March 31, 2026, sales slipped 2.8% to $2.413 billion as lower average pricing offset volume gains, but gross profit improved to $347.7 million and operating income increased to $162.7 million. Net income attributable to Pyxus was $14.6 million, or $0.56 per diluted share, and adjusted EBITDA reached a record $226.7 million.
Liquidity and balance sheet metrics strengthened: Q4 operating cash flow was $310.1 million, adjusted free cash flow was $352.1 million, cash and cash equivalents increased to $134.3 million, and net debt/adjusted EBITDA improved to 3.52x. For fiscal 2027, the company guides to $2.3–$2.5 billion of sales and $210–$240 million of adjusted EBITDA.
Pyxus International files its annual report showing $2,413.0 million in tobacco sales for the year ended March 31, 2026. The global leaf business remains the core, with Africa, Asia, Europe and other regions all contributing meaningfully.
The company carries $932.9 million of indebtedness and relies heavily on short- and long-term credit facilities, with $747.3 million available for borrowing at year-end. Tobacco inventories were $786.7 million, positioning Pyxus for more carry-over sales into fiscal 2027, but also tying up working capital.
Operations are highly concentrated: three multinational tobacco manufacturers each contributed at least 10% of annual revenue, and non-tobacco crops were less than 1% of sales. Pyxus employs about 3,300 people worldwide and faces risks from high leverage, volatile crop conditions, regulation of tobacco and nicotine products, and geopolitical and currency pressures across its many sourcing regions.
Pyxus International reported strong third quarter fiscal 2026 results, highlighted by net income of $16.9 million and adjusted EBITDA of $80.0 million, essentially matching last year’s record third quarter performance. Management reiterated that the company remains on track for one of its strongest years.
Third quarter sales and other operating revenues were $655.8 million, down from $778.3 million, mainly due to shipment timing in Africa and Europe and lower average pricing in South America tied to lower crop purchase costs. Despite lower revenue, gross margin improved to 15.2% from 15.0%, helped by larger South American crops and higher third‑party processing volumes.
For the first three quarters, sales were $1.73 billion, a 12.4% decline from $1.98 billion, while gross margin rose to 14.6% from 13.9%. Tobacco inventory increased to $959.8 million, in line with larger crops, and net debt rose by $199.4 million versus the prior year, with no outstanding borrowings on the $150.0 million ABL facility. Pyxus reaffirmed full‑year fiscal 2026 guidance, targeting net sales of $2.4–$2.6 billion and adjusted EBITDA of $215–$235 million.
Pyxus International, Inc. reported lower sales but stable quarterly profitability in its latest period. For the three months ended December 31, 2025, sales and other operating revenues fell 15.7% to $655.8 million, mainly from lower leaf tobacco volumes and prices, while gross margin ticked up to 15.2% due to favorable mix and stronger processing revenues.
Quarterly net income attributable to Pyxus was $16.9 million, down 10.6% from the prior year, but year-to-date profit dropped sharply to $0.2 million from $20.3 million as lower volumes, shipment timing and higher other expenses weighed on results. Operating cash flow was deeply negative at $(518.6) million for the nine-month period, driven by a large build in inventories and advances to suppliers tied to bigger crops.
Net debt rose to $1.16 billion, up from $960.0 million a year earlier, as the company relied more heavily on foreign seasonal lines of credit. Total tobacco inventories reached $959.8 million as of December 31, 2025, positioning Pyxus to support anticipated higher shipments later in the fiscal year but increasing working capital intensity and leverage.
Pyxus International, Inc. (PYYX) reported a new equity award to one of its directors. On November 20, 2025, the director received 10,980 restricted stock units (RSUs), each representing a contingent right to receive one share of Pyxus common stock.
The RSUs are earned for vesting based on continued board service through the earlier of August 14, 2026 or the commencement of the 2026 annual shareholders meeting, with a prorated amount earned if service ends earlier. Vesting is further contingent on the earliest of March 31, 2031, a defined Change in Control transaction, or Pyxus common stock being listed for trading on a registered or approved foreign securities exchange. Following this grant, the director beneficially owns 10,980 derivative securities directly.
Pyxus International, Inc. (PYYX) reported a director equity award of 10,980 restricted stock units (RSUs). Each RSU represents a right to receive one share of Pyxus common stock.
The RSUs were granted on November 20, 2025 and are earned based on continued board service through the earlier of August 14, 2026 or the company’s 2026 annual shareholders meeting, with prorated earning if service ends sooner. Vesting is further contingent on the earliest of March 31, 2031, a qualifying change in control transaction, or Pyxus common stock becoming listed for trading on a registered U.S. or approved foreign securities exchange.
Pyxus International, Inc. reported an equity grant to one of its directors in the form of 10,980 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Pyxus common stock at a future date.
The RSUs were awarded on November 20, 2025 and are to be earned for vesting based on continued board service through the earlier of August 14, 2026 or the start of the 2026 annual shareholders meeting, with prorated vesting if service ends earlier. Vesting is further contingent on the earliest of March 31, 2031, a defined change in control transaction, or the company’s common stock becoming listed on a registered or approved securities exchange.
Pyxus International, Inc. (PYYX) disclosed that one of its directors received 10,980 restricted stock units (RSUs) on November 20, 2025. Each RSU represents a contingent right to receive one share of Pyxus common stock at no exercise price.
The RSUs are earned for vesting based on continued board service through the earlier of August 14, 2026 or the start of the company’s 2026 annual shareholders meeting, with a prorated amount earned if service ends earlier. Actual vesting is further contingent on the earliest of March 31, 2031, a qualifying change in control transaction under the company’s 2020 Incentive Plan, or Pyxus common stock becoming listed for trading on a registered or approved securities exchange.
Pyxus International, Inc. (PYYX) reported an equity compensation grant to one of its directors. On November 20, 2025, the director received 10,980 restricted stock units (RSUs), each representing a contingent right to receive one share of Pyxus common stock. The RSUs are earned for vesting based on continued board service through the earlier of August 14, 2026 or the start of the 2026 annual shareholders meeting, with prorated earning if service ends earlier.
Actual vesting is further contingent on the earliest of three events: March 31, 2031; a qualifying Change in Control under the company’s 2020 Incentive Plan; or Pyxus common stock being listed for trading on a U.S. or approved foreign securities exchange.
Pyxus International, Inc. furnished an 8-K announcing it issued a press release with operating and financial results for the three and six months ended September 30, 2025. The press release is included as Exhibit 99.1.
The company notes the information is furnished, not filed under Section 18 of the Exchange Act. The report lists no securities registered under Section 12(b). The date of the report and press release is November 12, 2025.